QUEBEC CITY, Sept. 12 /CNW Telbec/ - Advitech Inc. ("Advitech" or the
"Corporation") (TSX Venture Exchange: AVI) announced today that a
post-marketing study conducted on patients suffering from psoriasis shows that
the use of Dermylex(TM) may benefit patients already using topical
corticosteroids. Using Dermylex(TM) with topical corticosteroids may create a
synergistic effect and improve overall treatment efficacy results. Therefore,
Dermylex(TM) might act as an adjuvant to topical corticosteroids.
